22.08.2017 15:00:00

Sales of CBD Products are Projected to Increase

NEW YORK, August 22, 2017 /PRNewswire/ --

According to a research report published by Hemp Business Journal and Vote Hemp, the Hemp Food, Body Care, and CBD products lead the U.S. hemp retail market and are projected to grow at a five year 22% CAGR. The report estimates that the total retail value of hemp products sold in the U.S. in 2016 was $688 million, and projected to grow to $1.8 billion in sales by 2020. Several categories of products such as shelled seed, protein powder, soaps and lotions have continued to show growing sales. Hemp CBD, a segment of the market with $130 million in sales and growing at a 53% AGR, contributed significantly to the $688 million in total sales according to the research. The Hemp CBD category archived popularity thanks to successful implementation of sales channels in natural and specialty products, smoke shops, and online verticals. Global Payout, Inc. (OTC: GOHE), OWC Pharmaceutical Research Corp. (OTC: OWCP), United Cannabis Corp. (OTC: CNAB), Kush Bottles, Inc. (OTC: KSHB), Easton Pharmaceuticals, Inc. (OTC: EAPH).

Cannabidiol (CBD) is the part of the cannabis plant that is usually used for medical purposes. Growth of the medical cannabis market is expected to accelerate as the products become more popular treatments for various medical applications such as chronic pain, post-traumatic stress disorder (PTSD), sleep disorders, anxiety, nerve pain and others. "The United States constitutes 35% of the global pharmaceutical market, the largest market in the world, and a major driver of the U.S. economy. It is one of many industries that will be impacted by the growth of the legal cannabis market and we are already starting to see that trend in legal medical states where use of key prescription drugs is down by 11%. If cannabis were to be adopted nationally, we would begin to see a trend of patients turning to medical cannabis as a substitute or complement to pharmaceuticals," said Giadha Aguirre De Carcer, CEO and Founder, New Frontier Data.

Global Payout, Inc. (OTC: GOHE) announced yesterday that its majority owned subsidiary, MoneyTrac Technology, Inc. has finalized a business development agreement with Pot Saver, a Southern California-based community periodical providing listings on discounted cannabis-related products for local dispensaries and shops. As per the agreement, MTRAC will provide Pot Saver with fundamental support and guidance needed to execute its go-to-market strategy.

The Company expects that as early as Q4 2017, this agreement will enable MTRAC to generate revenue earnings from service agreements facilitated on behalf of Pot Saver, while providing both companies an opportunity to benefit from rampant market growth.

"With the medical and recreational cannabis industry growing at an unprecedented rate in California, we are determined to be conscious of the multiple opportunities that currently exist, or that we can create for MoneyTrac to further expand its brand throughout the industry as well as tap into every available revenue source possible," said MTRAC COO Vanessa Luna. "This agreement with Pot Saver is an excellent opportunity for us to offer the industry-specific business development expertise we have acquired to help further Pot Saver's go-to-market strategy, while simultaneously creating a new source of revenue for our company as we continue to expand our own brand throughout the industry."

OWC Pharmaceutical Research Corp. (OTCQB: OWCP) and mediq Innovation Partners (mediq) announced earlier this year an agreement for the introduction of OWCP's active cannabinoid-based topical psoriasis cream to the German market. Frankfurt, Germany-based mediq has extensive experience, knowledge and a successful track record in enabling Israel-based companies to penetrate the European markets. Mediq's objectives for OWCP will consist of both scientific collaboration and most importantly the development of a commercial market for OWCP's proprietary, active cannabinoid-based topical psoriasis cream in Germany.

Commenting on the collaboration with OWCP, Jan Wende, managing director of mediq stated, "We're looking forward to initiating our efforts on behalf of OWCP in Europe, starting in our home market of Germany. Since German laws and regulations allow non-smokable forms of medical cannabis, we believe that OWCP's proprietary cannabinoid-based topical psoriasis cream is the right product at the right time."  

United Cannabis Corp. (OTCQB: CNAB) announced on August 15th that the United States Patent and Trademark Office (USPTO) has issued US Patent #9730911, granting exclusive rights to its proprietary formulations based on compounds extracted from cannabis plant materials; more specifically, the composition of matter pertaining to the use of phytocannabinoids, cannabinoids, and specific terpene profiles in liquid form. This composition of matter patent provides protection for United Cannabis' proprietary formulations. Earnest Blackmon, United Cannabis' Chief Executive Officer, commented on the approval, "This is a significant milestone for United Cannabis. Our primary objective has always been to develop unique and effective cannabinoid based products. This Patent is one the cornerstones of our business plan for obtaining FDA approval."

Kush Bottles, Inc. (OTCQB: KSHB) is a dynamic sales platform that provides unique products and services for both businesses and consumers in the cannabis industry. On August 1st, Kush Bottles announced that it reached an agreement with CannaKorp to develop customized packaging for the CannaCloud, the world's first single-use, pod-based vaporizing system. Nicholas Kovacevich, Chief Executive Officer of Kush Bottles, commented, "CannaKorp is one of the most innovative companies in the legal cannabis industry and we are proud to provide packaging solutions for this ground-breaking system. We look forward to working with them as they grow and roll-out products nationwide."

Easton Pharmaceuticals, Inc. (OTC: EAPH) is a diversified specialty pharmaceutical company involved in various pharmaceutical sectors and other growing industries. The company announced on August 16th, pursuant to its previously announced closing agreement with Canadian-based Alliance Group, Easton has advanced $575,000 towards its acquired interest in 45 acres of a 135-acre fully owned parcel of land for the cultivation, production and sale of medical/recreational marijuana to the cannabis industry and towards other revenue producing businesses.

Please SIGN UP NOW at http://www.FinancialBuzz.com To Receive Alerts on Trending Financial News from all these companies. "The Latest Buzz in Financial News"

Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia

Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com  

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. Financialbuzz.com has not been compensated directly by any of the companies mentioned here in this editorial. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For this release, FinancialBuzz.com has been compensated four thousand dollars for financial news dissemination and pr services by a non-affiliate third party for global payout, inc. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit: http://www.financialbuzz.com.

For further information:
info@financialbuzz.com  
+1-877-601-1879

Url: http://www.FinancialBuzz.com


SOURCE FinancialBuzz.com

Nachrichten zu Easton Pharmaceuticals Incmehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Easton Pharmaceuticals Incmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Easton Pharmaceuticals Inc 0,00 0,00% Easton Pharmaceuticals Inc